Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer

Hao Wang, Chenxin Zeng, Xin Li, Youjie Wang, Xinyi Li, Weihong Ge
  • Future Oncology, October 2018, Future Medicine
  • DOI: 10.2217/fon-2018-0692

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.2217/fon-2018-0692